SLC2A1 and Dravet syndrome: Despite the established benefits of KD in GLUT1‐DS, a small number of patients show limited or no response, a phenomenon referred to as “KD resistance.” This remains poorly defined and insufficiently studied, partly due to limited published data, inconsistent definitions, and variability in clinical presentation and outcome reporting across studies.